Research Journal of Pharmacology and Pharmacodynamics

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Recent Advancement Towards Treatment of Diabetes


Affiliations
1 Department of Pharmaceutical Chemistry, Shri Sarvajanik Pharmacy College, Mehsana, India
     

   Subscribe/Renew Journal


Diabetes is a chronic disease that occurs when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin it produces. Diabetes can damage the heart, blood vessels, eyes, kidneys, and nerves. In 2030, the figure of diabetic patients is expected to rise to 366 million. Diabetes is the fourth leading cause of global death by disease. Each year diabetes accounts for 3.8 million deaths. This article deals with recent advancement to wards treatment of diabetes. First it reviews emerging targets for diabetes like PTP-1B inhibitors, GSK-3 inhibitors and DPP-4 inhibitors. Second it describes recent nanotechnology research in the detection of insulin and blood sugar by implantable sensor and microphysiometer. In addition latest stem cell research occurs in diabetes treatment. At last this article give idea about working of insulin pump, glossary of pump and how pump can reduce the risk of complication of diabetes.

Keywords

Diabetes, PTP-1B Inhibitors, GSK-3 Inhibitors, DPP-4 Inhibitors, Nanotechnology, Insulin Pump, Stem Cell.
Subscription Login to verify subscription
User
Notifications
Font Size


  • World health organization. Fact sheet no. 312: what is diabetes? Available at: Http://www.who.int/mediacentre/factsheets/fs312/en/.Accessed on: 14 October, 2008.

  • International diabetes federation. Diabetes prevalence. Available at: http://www.idf.org/home/index.cfm?Node=264. Accessed on: 14 October, 2008.

  • World health organization. Diabetes action now booklet. Available at: Http://www.who.int/diabetes/booklet_html/en/print.html. Accessed on: 14 October, 2008.

  • International diabetes federation. Facts & figures: did you know? Available at: Http://www.idf.org/home/index.cfm?Unode=3b96906bc026-2fd3-87b73f80bc22682a. Accessed on: 14 October, 2008.

  • American diabetes association. 1 in 3 Americans born in 2000 will develop diabetes. Available at: Http://www.diabetes.org/for-media/scientific-sessions/06-14-03-2.jsp. Accessed on: 14 October, 2008.

  • International diabetes federation. The human, social and economic impact of diabetes.

  • World health organization. "definition, diagnosis and classification of diabetes mellitus and its complications: report of a who consultation. Part 1. Diagnosis and classification of diabetesmellitus". Http://www.who.int/diabetes/publications/en/. Retrieved on 2007-05-29.

  • Qaseem A, Vijan S, Snow V, Cross JT, Weiss KB, Owens DK (September 2007). "glycemic control and type 2 diabetes mellitus: the optimal hemoglobin a1c targets. A guidance statement from the american college of physicians". Ann. Intern. Med. 147(6): 417-22. Pmid 17876024.Http://www.annals.org/cgi/content/full/147/6/417. Retrieved on 2008-07-19.

  • "clinical practice guidelines" http://www.diabetes.ca/cpg2003/chapters.aspx. Retrieved on 2008-07-19.

  • Leung C. et al., The difluoromethylenesulfonic acid group as a monoanionic phosphate surrogate for obtaining PTP-1B inhibitors. Bioorg. Med. Chem., 2002, 10, 2309-2323.

  • Zhang ZY, Protein tyrosine phosphatases: prospects for therapeutics. Curr. Opin. Chem. Biol., 2001, 5, 416-423.

  • Huijsduijnen VRH, Bombrun A, and Swinnen D, Selecting protein tyrosine phosphatases as drug targets. Drug Discovery Today, 2002, 7, 1013-1019.

  • Masiello P, Broca C, Gross R, Roye M, Manteghetti M, Hillaire-Buys D, Novelli M, Ribes G. Diabetes 1998, 47, 224.

  • Ortiz-Andrade RR, Rodriguez-Lopez V, Garduno-Ramirez ML, Castillo-Espana, P, Estrada-Soto SJ. Ethnopharmacol. 2005, 101, 37.

  • Chemical Computing Group Inc., 1255 University Street, Montreal, Quebec, Canada H3B 3X3, 2005. Molecular Operating Environment (MOE). http://www.chemcomp.com.

  • Website: http://www.ibmh.msk.su/PASS.

  • Wauwe JV, and Haefner B, Glycogen synthase kinase-3 as drug target: From wallflower to center of attention. Drug News Perspect. 2003, 16, 557-565.

  • Ryves WJ, and Harwood AJ, Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem. Biophys. Res. Commun., 2001, 280, 720-725.

  • Zhang F, Christopher JP, Laura S, Nadia G, and Klein PS, Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. J. Biol. Chem., 2003, 278, 33067-33077.

  • Kunick C, Lauenroth C, Wieking K, Schultz C, Lemcke T, and Flemming SJ, Evaluation and comparison of 3D-QSAR CoMSIA models for CDK1, CDK5 and GSK-3 inhibition by paullones. J. Med. Chem., 2004, 47, 22-36.

  • Kunick C, Lauenroth C, Leost M, Meijer L, and Lemcke T, 1-Azakenpaullone is a selective inhibitor of glycogen synthasekinase-3b. Bioorg. Med. Chem. Lett., 2004, 14, 413-416.

  • Meijer L, Skaltsounis A, Magiatis P, and Knockaert M, GSK-3 selective inhibitors derived from Tyrian purple indirubins. Chem. Biol., 2003, 10, 1255-1266.

  • Smith DG, Buffet M, Ashley EF, Haigh D, Ife RJ, and Ward RW., Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3. Bioorg. Med. Chem. Lett., 2003, 13, 3049-3053.

  • Gee-Hong K, Prouty C, Angelis AD, Shen L, ONeill DJ,Shah C. and Jolliffe L, Synthesis and discovery of macrocyclicpolyoxygenatebis-7-azaindolylmaleimides as a novel series of potentand highly selective glycogen synthase kinase-3b inhibitors.J. Med. Chem., 2003, 46, 4021-4031.

  • Shen, L, Prouty, C, Conway BR., Jun, ZX. and Gee-Hong K., Synthesis and biological evaluation of novel macrocyclic bis-7-azaindolylmaleimides as potent and highly selective glycogen synthasekinase-3b (GSK-3b) inhibitors. Bioorg. Med. Chem., 2004, 12, 1-1

  • Zhang, HC., Ye H., Conway B R., Derian CK. and Maryanoff BC., 3-(7-Azaindolyl)-4-arylmaleimides as potent, selective inhibitorsof glycogen synthase kinase-3. Bioorg. Med. Chem. Lett., 2004, 14, 3245-3250.

  • Bowler AN., Kilburn JP., Engelhardt S., Danielsen GM. and Kurthzals P., Oxadiazepines with glucose lowering properties. 16th Int. Symp. Med. Chem., 2000, www.google.com.

  • Olesen P, Kurthzhals P., Worsaee H, Hansen BF, Sorensen AI. and Bowler A. N., Synthesis and in vitro characterization of 1-(4-aminofurazan-3-yl)-5-dialkylamino methyl-1H-[1, 2, 3] triazole-4-carboxylic acid derivatives. J. Med. Chem., 2003, 46, 3333-3341.

  • Olesen P, Kurthzhals P, Worsaee H., Hansen, B. F., Sorensen, A. I. and Bowler, A. N., Furazanyl-triazole derivatives for the treatment of diseases. 2002, WO 02/032896.

  • Sorensen AR., Worsaae H., Hansen BF, Kurthzhals P, Bowler AN, and Olesen PH, 2, 4-Diaminothizole derivatives and their use as glycogen synthase kinase-3 (GSK-3) inhibitors. 2001, WO 01/056567.

  • Bowler AN, and Hansen BF, 2, 4-Diaminothiazole derivatives and their use as glycogen synthase kinase-3 (GSK-3) inhibitors. 2003, WO 03/011843.

  • Cochran J., Nanthakumar J., Harrigton E. and Wang J., Thiazole derivatives useful as inhibitors of protein kinases. 2002, WO 02/096905.

  • Moon YC, Green J, Davies R, Choquette D, Pierce A, and Ledeboer M, 5-(2-aminopyrimidine-4-yl) benzisoxazoles as protein kinase inhibitors. 2002, WO 02/102800.

  • Green J, Arnost MJ, and Pierce A, Pyrazolone derivatives as inhibitors of GSK-3. 2003, WO 03/011287.

  • Savithri R. and Nuss J., Pyrazine based inhibitors of glycogen synthase kinase-3. 2001, WO 01/044206.

  • Desai M., Ramurthy S, Nuss J M. and Boyce R, Pyrimidine based inhibitors of GSK-3. 2002, WO 02/020495.

  • Cline GW. et al., Effects of novel glycogen synthase kinase-3 inhibitors on insulin stimulated glucose metabolism in zucker diabetic fatty (fa/fa) rats. Diabetes, 2002, 51, 2903-2910.

  • Fehse F, Trautmann M, Holst JJ, Halseth AE, Nanayakkara N, Nielsen LL, et al. Exenatide augments first-and secondphase insulin secretion in response To intravenous glucose in subjects with type 2 diabetes. J clin endocrinol metab 2005; 90(11):5991-7. Epub 2005 Sep 6.

  • Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36(8):741-4.

  • Pospisilik JA, Martin J, Doty T, Ehses JA, Pamir N, Lynn FC, et al. Dipeptidyl Peptidase iv inhibitor treatment stimulates beta-cell survival and islet Neogenesis in streptozotocininduced diabetic rats. Diabetes 2003; 52(3):741-50.

  • Mu J, Woods J, Zhou YP, Roy RS, Li Z, Zycband E, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic{beta}-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006; 55(6):1695-704.

  • Microphysiometer using multiwall carbon nanotubes enables constant realtime monitoring of microliters of insulin [electronic resource] [accessed 2008 apr 18].Available from: URL: http://nextbigfuture.com/2008/04/microphysiometerusing-multiwall carbon.html.

  • Liang HF, Hong MH, Ho RM, Chung CK, Lin YH, Chen CH and Sung HW. Novel method using a temperature-sensitive polymer (methylcellulose) to thermally gel aqueous alginate as a ph-sensitive hydrogel biomacromolecules 5, 1917-25(2004).

  • Smyth s and heron a. Diabetes and obesity: the twin epidemics nat. Med. 12, 75-80 (2006).

  • Krauland AH, Guggi D and Bernkop-Schnurch A. Oralinsulin delivery: the potential of thiolated chitosan-insulin tablets on non-diabetic rats j. Control. Release 95, 547-55(2004).

  • Borchard G, Lueßen HL, De Boer AG, Verhoef JC, Lehr CM And Junginger H E. The potential of mucoadhesive polymers in enhancing intestinal peptide drug absorption. Iii: effects of chitosan-glutamate and carbomer on epithelial tight junctions in vitro j. Control. Release 39, 131-8(1996).

  • Kotz'e AF, Lueßen HL, De Leeuw BJ, De Boer (A)BG, Verhoef JC And Junginger HE. Comparison of the effect of different chitosan salts and n-trimethyl chitosan chloride on the permeability of intestinal epithelial cells (caco-2) j. Control. Release 51, 35-46(1998).

  • Lamprecht A, Koenig P, Ubrich N, Maincent P And Neumann D. Low molecular weight heparin nanoparticles: mucoadhesion and behaviour in caco-2 cells nanotechnology 17, 3673-80(2006).

  • Ramadas M, Paul W, Dileep KJ, Anitha Y And Sharma CP. Lipoinsulin encapsulated alginate-chitosan capsules: intestinal delivery in diabetic rats j. Microencapsul 17, 405-11 (2000).

  • Agnihotri SA, Mallikarjuna NN and Aminabhavi TM. Recent advances on chitosan-based micro-and nanoparticles in drug delivery J. Control. Release 100, 5-28(2004).

  • Gerardo P. Carino, Edith Mathiowitz. Oral insulin delivery; Advanced Drug Delivery Reviews 35,249-257(1999).

  • Hanazaki K, Nose Y, Brunicardi FC. Artificial endocrine pancreas. J Am Coll Surg [electronic resource] [accessed 2006 Jan 20]. Available from: URL: http://www.sciencedirect.com/science?_ob=Article.

  • Freitas RA. Current status of nanomedicine and medical nanorobotics [electronic resource] [accessed 2006 Jan 20]. Available from:url:http://www.nanomedicine.com/papers/nmrevmar05.pdf.

  • Freitas RA. The future of nanofabrication and molecular scale devices in nanomedicine. [Electronic resource] [Accessed 2006 Jan 20]. Available from: URL: http://www.rfreitas.com/nano/futurenanofabnmed.htm.

  • Insulin nanopump for accurate drug delivery. [Electronic resource] [Accessed 2008 Aug 15]. Available from: http://thefutureofthings.com/news/1286/insulin-nanopumpfor-accuratedrug-delivery.html.

  • Eeka Nas Du'i, Kvalitetniji I Jednostavniji 'Ivot. Medicinar [electronic resource] 2003 dec [accessed 2005 Feb 6]. Available from: URL: Http://medicinar.mef.hr/tekstovi.php?id=39.

  • Stem Cells doi:10.1634/stemcells.2005-0367, published online March 23, 2006.

  • Yoshida S et al., Human cord blood-derived cells generate insulin producing cells in vivo, Stem Cells 23, 1409-1416,October 2005.

  • Sapir et al., Cell-replacement therapy for diabetes: generating functional insulin-producing tissue from adult human liver cells, PNAS 102, 7964-7969, 17 May 2005. 60. Oh S H, et al., Adult bone marrow-derived cells transdifferentiating into insulin-producing cells for the treatment of type I diabetes, Lab Invest 84, 607-617, May 2004.

  • Fujikawa T et al, American Journal of Pathology 166, 1781-1791, June 2005.

  • Weissberg-benchell j, antisdel lomaglio j, seshadri r. Insulin pump therapy: a meta-analysis. Diabetes care. 2003; 26(4):1079-87.

  • Rudolf jw, hirsch ib. Assessment of therapy with continuous subcutaneous insulin infusion in an academic diabetes clinic. Endocrine practice. 2002; 8:401-5.

  • Bode BW, Sabbah HT, Gross TM, et al. Diabetesmanagement in the new millenium using insulin pump therapy. Diabetes metab res rev. 2002; 18(suppl 1):s14-20.

  • Linkeshova R, Raoul M, Bott U, et al. Less severe hypoglycameia, better metabolic control, and improved quality of life in type 1 diabetes mellitus with continuous subcutaneous insulin infusion (csii) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years. Diabetes med. 2002; 19(9):746-51.

  • Weissberg-Benchell J, Antisdel Lomaglio J, Seshadri R. Insulin pump therapy: a meta-analysis. Diabetes care. 2003; 26(4):1079-87.

  • Boland EA, Grey M, Oesterle A, et al. Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes.

  • Chantelau E, Spraul M, Muhlhauser I, et al. Long-term safety, efficacy and side effects of continuous subcutaneous insulin infusion treatment for type 1 (insulin dependent) diabetes mellitus: a one centre experience. Diabetologia. 1989; 32(7):421-6.

  • Diabetes control and complications trial research group: lifetime benefits and costs of intensive therapy as practiced in the dcct. Jama, 1996; 276:1409-1415.

  • Bode BW, Steed RD, and Davidson PD: reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type 1 diabetes. Diabetes care, 1996; 19:324-327.


Abstract Views: 207

PDF Views: 0




  • Recent Advancement Towards Treatment of Diabetes

Abstract Views: 207  |  PDF Views: 0

Authors

Ishan Panchal
Department of Pharmaceutical Chemistry, Shri Sarvajanik Pharmacy College, Mehsana, India
B. Panigrahi
Department of Pharmaceutical Chemistry, Shri Sarvajanik Pharmacy College, Mehsana, India
C. N. Patel
Department of Pharmaceutical Chemistry, Shri Sarvajanik Pharmacy College, Mehsana, India

Abstract


Diabetes is a chronic disease that occurs when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin it produces. Diabetes can damage the heart, blood vessels, eyes, kidneys, and nerves. In 2030, the figure of diabetic patients is expected to rise to 366 million. Diabetes is the fourth leading cause of global death by disease. Each year diabetes accounts for 3.8 million deaths. This article deals with recent advancement to wards treatment of diabetes. First it reviews emerging targets for diabetes like PTP-1B inhibitors, GSK-3 inhibitors and DPP-4 inhibitors. Second it describes recent nanotechnology research in the detection of insulin and blood sugar by implantable sensor and microphysiometer. In addition latest stem cell research occurs in diabetes treatment. At last this article give idea about working of insulin pump, glossary of pump and how pump can reduce the risk of complication of diabetes.

Keywords


Diabetes, PTP-1B Inhibitors, GSK-3 Inhibitors, DPP-4 Inhibitors, Nanotechnology, Insulin Pump, Stem Cell.

References